Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Key Highlights
- ➤Phase 1b FIH study for PRP planned Q1, 2027, enrolling up to 50 patients
- ➤$7.5 million gross proceeds raised in fiscal 2025-26
- ➤$100 million private placement agreement entered to accelerate clinical development
- ➤$5.0 million share repurchase authorized; $500,000 first tranche completed
- ➤Net loss $18.86 million in fiscal 2025-26, down from $58.92 million
Expert Statements
James Nathanielsz, Chief Executive Officer of Propanc Biopharma, Inc.
“The Propanc Executive team are delighted with advancements made in the past financial year.”
James Nathanielsz, Chief Executive Officer of Propanc Biopharma, Inc.
“The Company is poised to capitalize on the foundation set in the next financial year with the advancement of PRP to a Phase 1b FIH study in up to 50 advanced cancer patients with solid tumors such as pancreatic, ovarian and refractory prostate cancers.”
James Nathanielsz, Chief Executive Officer of Propanc Biopharma, Inc.
“PRP is a potential breakthrough therapy that modulates the tumor micro-environment by targeting the EMT (epithelial-mesenchymal transition) process, which drives metastasis, invasion and recurrence from CSCs (cancer stem cells) which often lie dormant, post treatment, causing the cancer to return and spread.”
James Nathanielsz, Chief Executive Officer of Propanc Biopharma, Inc.
“We look forward to executing our scientific and clinical research activities in the 2026-2027 financial year.”
MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported year-end financial results as of June 30, 2026 (Year end June 30).
To commence a world-first Phase 1b FIH study of PRP in Q1, 2027
Get started
Create a free account to read the full story.